Transaction · 0001193125-26-414688

Vieira Roberto Wandenkolk

Vieira Roberto Wandenkolk, PRES, reported an open-market or private sale at CORCEPT THERAPEUTICS INC involving 5147.000000 shares for an estimated $600063.00. Reported holdings after the transaction were 3946.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SPRES
CORTCORCEPT THERAPEUTICS INC
Filing timeOct 05
Trade dateOct 02, 2026
Filing · SECView on SEC
InsiderProfile
% of reported position traded56.6%Shares sold ÷ (holdings after + shares sold). Estimated position before: 9,093 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$122.03
Pre-filing
1mo ago -9.5%1w ago -4.9%1d ago -6.6%
Returns since
7d30d90d180d1y

CORT price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
CORT since 2026-10-05Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001193125-26-414688
Common Stock
Transaction date
Oct 02, 2026
Filed Oct 05, 2026, 11:58 PM · 3d delay
Shares
5.14k sh
$116.59 per share
Estimated value
-$600k
Computed from shares × price
Holdings after
3.94k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Direct Ownership Large Holdings Reduction Large Sale Repeat Seller 10b5-1 Detected
-4score
Filing-only score

-4

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President, Oncology

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the…

  2. F2

    This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the Reporting Person being appointed an officer of the Issuer, which was in effect at the…

  3. F3

    Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.03 to $114.90 per share. Information on the exact number of shares sold at each…

  4. F4

    Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.16 to $116.04 per share. Information on the exact number of shares sold at each…

  5. F5

    Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.24 to $117.22 per share. Information on the exact number of shares sold at each…

  6. F6

    Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable…

Original filing · 0001193125-26-414688
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

CORT